Huiyu Pharmaceuticals announced that its subsidiary SEACROSS PHARMACEUTICALS LIMITED recently received the marketing authorization for the company's product cyclophosphamide for injection approved by the UK Medicines and Healthcare Products Regulatory Agency. The drug is mainly used to treat chronic lymphocytic leukemia (CLL) and other diseases. The company's cyclophosphamide for injection has obtained marketing authorization in China, the United Kingdom, Ireland, Portugal, France, the Netherlands, Italy, and Spain, and has submitted a registration application in Germany. Obtaining the UK marketing authorization will help the company enrich its product pipeline in the international market and enhance its brand image in the market.